Danny Chou is an Assistant Professor of Pediatrics (Endocrinology and Diabetes) at Stanford University. He received his Ph.D. from Harvard University, working in the lab of Prof. Stuart Schreiber in 2011. His Ph.D. research involved the identification of suppressors of cytokine-induced apoptosis in pancreatic beta cells. He then moved to MIT, where he was a JDRF Postdoctoral Fellow in the Department of Chemical Engineering. He worked under the guidance of Profs. Robert Langer and Daniel Anderson, focusing on the development of glucose-responsive insulin derivatives.

Danny started his independent career in the Department of Biochemistry at the University of Utah in August 2014. At Utah, Danny's research focused on protein and peptide therapeutics for treating human diseases. In 2020, Danny moved his research lab to Stanford University to continue their efforts in developing novel peptide therapeutics.

The main research direction of the Chou lab is to use synthetic and enzymatic methods to engineer peptides with enhanced therapeutic potential focusing on insulin, interleukins and natural products from cone snail venom. He has received recognitions including a BPS Young Investigator Award, JDRF Career Development Award, Vertex Scholar, JDRF Postdoctoral Fellow and ADA Junior Faculty Award.